Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study of SYH2053 when administered subcutaneously to subjects with normal and elevated LDL-C.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06229548
Study type Interventional
Source CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Contact Clinical Trials Information Group officer
Phone +86-0311-69085587
Email ctr-contact@cspc.cn
Status Not yet recruiting
Phase Phase 1
Start date January 26, 2024
Completion date December 30, 2024

See also
  Status Clinical Trial Phase
Completed NCT04382521 - A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions N/A
Not yet recruiting NCT02593487 - Effect of Rosuvastatin Therapy on HDL2 Level Phase 4
Active, not recruiting NCT02697422 - Veteran Peer Coaches Optimizing and Advancing Cardiac Health N/A
Completed NCT04469673 - A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia.. Phase 1/Phase 2
Recruiting NCT05912296 - A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022 Phase 1
Active, not recruiting NCT05432544 - Safety and Tolerability of SHR-1918 in Healthy Subjects Phase 1
Completed NCT03950752 - Effect of Consumption of Bagel Without Palm Oil on Postprandial Lipidemia N/A
Completed NCT05532800 - The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia Phase 3
Completed NCT04781114 - The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia Phase 3
Active, not recruiting NCT04515927 - To Evaluate the Efficacy and Safety of JS002 in HoFH Patients Phase 2